Shenzhen Hepalink Pharmaceutical Group Co., Ltd (Hepalink) distributes its product, Heparin Sodium API in the global market to internationally renowned pharmaceutical companies, such as Sanofi-Aventis, Fresenius -Kabi, and Novartis.
Hepalink was established in 1998 and restructured in 2007 to be a limited liability company. Hepalink went public and was listed on the Shenzhen Stock Exchange on May 6, 2010 (stock code "002399"). Hepalink’s headquarters are located in the Shenzhen High-Tech Park.
Hepalink has created a proprietary process for dealing with impurities and composition separation and activity release technologies in the production of Heparin Sodium API. Hepalink has established a comprehensive quality management system in line with China GMP standards and the US and European cGMP standards and regulations. Hepalink is approved by the U.S. FDA and EU regulatory authorities, and is also one of the primary participants in the revision of the USP pharmacopeia standards.
Hepalink also has successfully undertaken several National Science and Technology Projects, such as the National Bio-tech Industrialization Demonstration Project, the National Torch Project, and the National Key Technology Innovation Project. Through these projects, Hepalink has made a significant contribution to the technological progress of China's Heparin industry, and export capabilities.
Hepalink, as a leading high-tech enterprise, has received numerous awards, including the National Award for Technology Innovation and Outstanding New Products, the award for the Enterprise with Outstanding Contributions for the Past 30 Years in the Shenzhen Special Economic Zone, the Shenzhen Excellent Private Enterprise award, the Shenzhen Excellent and Strong SME award, and the Shenzhen Leading Private Enterprise award.